Advancements in the Epidemiology, Diagnosis and Treatment of Hypertrophic Cardiomyopathy
A special issue of Journal of Cardiovascular Development and Disease (ISSN 2308-3425).
Deadline for manuscript submissions: 15 February 2025 | Viewed by 1905
Special Issue Editor
Interests: cardiac imaging; HOCM; hypertrophic cardiomyopathy; ischemic heart disease; strain echocardiography; valvular heart disease
Special Issue Information
Dear Colleagues,
Hypertrophic cardiomyopathy is a heterogeneous clinical disorder with a variable morphologic expression and an increasingly recognized prevalence in the cardiovascular patient community. In the past decade, we have seen exponential growth in the available modalities for patient diagnosis and risk stratification, as well as in treatment options ranging from medical therapy to percutaneous and surgical interventions. The aim of this Special Issue is to highlight this progress from the perspective of international experts across multi-disciplinary modalities via review articles, brief editorials, case reports, or original research. We encourage all interested authors to submit their work and share their experiences of this growing and complex patient population.
Dr. Christos G. Mihos
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- alcohol septal ablation
- CHF
- heart failure
- HOCM
- hypertrophic cardiomyopathy
- mavacamten
- mitral valve regurgitation
- septal myectomy
- systolic anterior motion
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Tentative title: Contemporary Updates in the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
Abstract: Hypertrophic cardiomyopathy (HCM) is characterized by hypertrophied myocardial tissue, most commonly due to genetic mutations in sarcomere proteins. This can lead to complications such as arrhythmias, sudden cardiac death, heart failure, syncope, mitral regurgitation, and myocardial ischemia. While we have come a long way in our understanding of the pathophysiology, genetics, and epidemiology of HCM, there have recently been significant advancements in diagnosis and treatment options for this disease. Updates in imaging practices, including in echocardiography, electrocardiography, and magnetic resonance imaging, have furthered our ability to accurately diagnose HCM. Advancements in pharmacologic therapies have reshaped the landscape of treatment. Additionally, innovation in procedural techniques have provided an effective management option if refractory to treatment with medications alone. These advancements have contributed to a significant decrease in mortality for patients diagnosed with HCM. Overall, the progress that has been made so far, coupled with extensive current and future research endeavors, will continue to shape the future of advancements in managing HCM.
Author: Michael V. DiCaro
Affiliation: Department of Medicine, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV 89102, USA